Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria

Sun,Quan; Shi,Jingxiang; Ren,Chaoyi; Du,Zhi; Shu,Guiming; Wang,Yijun

doi:10.3892/ol.2020.11529

Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria

Authors:
- Quan Sun
- Jingxiang Shi
- Chaoyi Ren
- Zhi Du
- Guiming Shu
- Yijun Wang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin 300170, P.R. China
Published online on: April 10, 2020 https://doi.org/10.3892/ol.2020.11529
Pages: 4066-4076
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the efficacy of microwave ablation (MWA) and surgical resection (RES) for the treatment of hepatocellular carcinoma (HCC) conforming to the Milan criteria and the associated short‑ and long‑term survival rates. The baseline characteristics were obtained from 231 patients with HCC who met the Milan criteria. To compare the mortality rates between groups, survival analysis was conducted using the Kaplan‑Meier method and the log‑rank test. The factors associated with the survival rate were analyzed using Cox proportional hazard models. A total of 115 patients underwent RES, and 116 were treated with MWA. No significant differences were observed in the 1‑, 3‑ and 5‑year OS rates and the 1‑year DFS rate between the two groups. The 7‑ and 10‑year OS rates and the 3‑, 5‑, 7‑ and 10‑year DFS rates of the RES group were significantly higher compared with those in the MWA group (P=0.004, P=0.002, P=0.003 and P=0.002, respectively). In addition, no marked differences were observed in the OS and DFS rates between the two groups of patients with solitary HCC lesions ≤3 cm (P=0.066 and P=0.056) and in the OS of those with solitary lesions of 3‑5 cm (P=0.133); however the DFS of patients with single 3‑5 cm HCC lesions in the RES group was notably higher compared with the MWA group (P=0.027). The Cox proportional hazard model revealed that age, hepatitis B and C virus infection, tumor size, number, platelet count and the type of treatment intervention were risk factors affecting the survival and recurrence in patients with HCC. These results suggested that RES may provide superior survival benefits compared with MWA for patients with HCC who meet the Milan criteria.

View Figures

View References

1	Cross TJS and Evans JC: Transarterial embolization therapies in hepatocellular carcinoma: Principles of management: From mechanisms to management. Liver Cancers. Springer International Publishing Corp.; Berlin: pp. 123–138. 2019, View Article : Google Scholar
2	Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA and Bray F: Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2:600–611. 2018. View Article : Google Scholar
3	Cong WM, Bu H and Chen J, Dong H, Zhu YY, Feng LH and Chen J; Guideline Committee, : Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 22:9279–9287. 2016. View Article : Google Scholar : PubMed/NCBI
4	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chen WQ, Zheng RS and Zhang SW: Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 32:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bureau of Medical Administration National Health and Family Planning Comission of the People's Republic of China, . Diagnosis, management, and treatment of hepatocellular carcinoma (V2017). Zhonghua Gan Zang Bing Za Zhi. 25:886–895. 2017.(In Chinese). PubMed/NCBI
7	Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, et al: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 66:545–551. 2017. View Article : Google Scholar : PubMed/NCBI
8	Klein S and Dufour JF: Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepat Oncol. 4:83–98. 2017. View Article : Google Scholar : PubMed/NCBI
9	Boyer TD and Haskal ZJ; American Association for the Study of Liver Diseases, : The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009. Hepatology. 51:3062010. View Article : Google Scholar : PubMed/NCBI
10	European Association for the Study of the Liver. Electronic address, . simpleeasloffice@easloffice.eu; European Association for the Study of the Liver: EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
11	Fukuda H: European organization for research and treatment of cancer. Jpn J Clin Oncol. 30:1692000.PubMed/NCBI
12	Zhou Y, Xu X, Ding J, Jing X, Wang F, Wang Y and Wang P: Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther. 14:40–45. 2018. View Article : Google Scholar : PubMed/NCBI
13	Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M and Chen MS: Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: A retrospective comparative study. Radiology. 262:1022–1033. 2012. View Article : Google Scholar : PubMed/NCBI
14	Shi J, Sun Q, Wang Y, Jing X, Ding J, Yuan Q, Ren C, Shan S, Wang Y and Du Z: Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. J Gastroenterol Hepatol. 29:1500–1507. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 1:52–60. 2010. View Article : Google Scholar
16	Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, et al: Image-guided tumor ablation: Standardization of terminology and reporting criteria. Radiology. 235:728–739. 2005. View Article : Google Scholar : PubMed/NCBI
17	Llovet JM and Hernandez-Gea V: Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 20:2072–2079. 2014. View Article : Google Scholar : PubMed/NCBI
18	Li X, Li B, Li B, Guo T, Sun Z, Li X, Chen L, Chen W, Chen P, Mao Y and Zeng Y: ITIH4: Effective serum marker, early warning and diagnosis, hepatocellular carcinoma. Pathol Oncol Res. 24:663–670. 2018. View Article : Google Scholar : PubMed/NCBI
19	Bréchot C: Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterology. 127 (5 Suppl 1):S56–S61. 2004. View Article : Google Scholar : PubMed/NCBI
20	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ and Lan WY: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 243:321–328. 2006. View Article : Google Scholar : PubMed/NCBI
22	Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P and Dong J: A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 57:794–802. 2012. View Article : Google Scholar : PubMed/NCBI
23	Thandassery RB, Goenka U and Goenka MK: Role of local ablative therapy for hepatocellular carcinoma. J Clin Exp Hepatol. 4 (Suppl 3):S104–S111. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yan X, Fu BM, Tang B, et al: Progress in clinical research of radiofrequency ablation for primary liver cancer. J Hepato Surg. 1:87–89. 2016.
25	Lau WY and Lai EC: The current role of radiofrequency ablation in the management of hepatocellular carcinoma: A systematic review. Ann Surg. 249:20–25. 2009. View Article : Google Scholar : PubMed/NCBI
26	Poggi G, Tosoratti N, Montagna B and Picchi C: Microwave ablation of hepatocellular carcinoma. World J Hepatol. 7:2578–2589. 2015. View Article : Google Scholar : PubMed/NCBI
27	Wright AS, Sampson LA, Warner TF, Mahvi DM and Lee FT Jr: Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 236:132–139. 2005. View Article : Google Scholar : PubMed/NCBI
28	Lucchina N, Tsetis D, Ierardi AM, Giorlando F, Macchi E, Kehagias E, Duka E, Fontana F, Livraghi L and Carrafiello G: Current role of microwave ablation in the treatment of small hepatocellular carcinomas. Ann Gastroenterol. 29:460–465. 2016.PubMed/NCBI
29	Wang JH, Wang CC, Hung CH, Chen CL and Lu SN: Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 56:412–418. 2012. View Article : Google Scholar : PubMed/NCBI
30	Harada N, Shirabe K, Maeda T, Kayashima H, Takaki S and Maehara Y: Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resection versus radiofrequency ablation. World J Surg. 40:1709–1719. 2016. View Article : Google Scholar : PubMed/NCBI
31	Kim SJ, Lee KK and Kim DG: Tumor size predicts the biological behavior and influence of operative modalities in hepatocellular carcinoma. Hepatogastroenterology. 57:121–126. 2010.PubMed/NCBI
32	Chen X, Zhang B, Yin X, Ren Z, Qiu S and Zhou J: Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 139:773–781. 2013. View Article : Google Scholar : PubMed/NCBI
33	Lazzara C, Navarra G, Lazzara S, Barbera A, Saitta C, Raimondo G, Latteri S and Curro G: Does the margin width influence recurrence rate in liver surgery for hepatocellular carcinoma smaller than 5 cm? Eur Rev Med Pharmacol Sci. 21:523–529. 2017.PubMed/NCBI
34	Qian GJ, Wang N, Shen Q, Sheng YH, Zhao JQ, Kuang M, Liu GJ and Wu MC: Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: Experimental and clinical studies. Eur Radiol. 22:1983–1990. 2012. View Article : Google Scholar : PubMed/NCBI
35	Huo TI, Liu WY, Wu JC, Huang YH, King KL, Loong CC, Lee PC, Chang FY and Lee SD: Deterioration of hepatic functional reserve in patient with hepatocellular carcinoma after resection: Incidence risk factors, and association with intrahepatic tumor recurrence. World J Surg. 28:258–262. 2004. View Article : Google Scholar : PubMed/NCBI
36	Yang W: Current status and prospective of imaging guided radiofrequency ablation in medium to large sized hepatocellular carcinomas. World Chin J Digestol. 30:47712015.(In Chinese). View Article : Google Scholar
37	Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, Brunello F, Pinna AD, Giorgio A, Giulini SM, et al: Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol. 59:89–97. 2013. View Article : Google Scholar : PubMed/NCBI
38	Zhang P, Gu A and Shi DM: Analysis of the status of postoperative recurrence and metastasis of hepatocellular carcinoma and its influencing factors. Oncol Prog. 4:2017.
39	Li T, Wang SK, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L and Fan J: Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. Liver Int. 36:284–292. 2016. View Article : Google Scholar : PubMed/NCBI
40	Huang JQ, Peng MH, Zou YQ, Yang DH, Chen B and Xiao KY: Analysis of risk factors for early recurrence of primary hepatocellular carcinoma after radical hepatectomy. Chinese J Practl Surg. 5:418–420. 2009.(In Chinese).